Myelodysplastic Syndromes (MDS)

SF3B1 Variant in MDS Found to Identify Distinct Disease Entities

Original Publication Date
Article Source
External Web Content
For the first time, an international working group of experts in myelodysplastic syndromes (MDS) proposed the recognition of the SF3B1 variant as a distinct nosologic entity based on the presence of a non-inheritable genetic mutation that causes the disease.1 SF3B1 mutation…

Guidance for Bone Marrow Failure Patients to Protect Against Coronavirus (COVID-19)

This content has been prepared in consultation with AAMDSIF Medical Advisory Board Chair Mikkael Sekeres MD, MS of Sylvester Comprehensive Cancer Center, University of Miami and Co-Chair Olatoyosi Odenike MD of the University of Chicago with additional review by Amy DeZern, MD, Johns Hopkins and Carlos De Castro, MD, Duke. ( November 2022)

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)

The 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of

Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.